Safety of hormone replacement therapy following risk-reducing salpingo-oophorectomy: systematic review of literature and guidelines

References

• ACOG Practice Bulletin No. 103. Hereditary breast and ovarian cancer syndrome. Obstet Gynecol 2009;113:957–66
   PubMedGoogle Scholar
• Reade CJ, Riva JJ, Busse JW, et al. Risks and benefits of screening asymptomatic women for ovarian cancer: a systematic review and meta-analysis. Gynecologic Oncol 2013;130:674–81
   PubMed Web of Science ®Google Scholar
• van Driel CM, de Bock GH, Arts HJ, et al. Stopping ovarian cancer screening in BRCA1/2 mutation carriers: effects on risk management decisions & outcome of risk-reducing salpingo-oophorectomy specimens. Maturitas 2015;80:318–22
   PubMed Web of Science ®Google Scholar
• Kauff ND, Satagopan JM, Robson ME, et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 2002;346:1609–15
   PubMed Web of Science ®Google Scholar
• Rebbeck TR, Lynch HT, Neuhausen SL, et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 2002;346:1616–22
   PubMed Web of Science ®Google Scholar
• Kenkhuis MJ, de Bock GH, Elferink PO, et al. Short-term surgical outcome and safety of risk reducing salpingo-oophorectomy in BRCA1/2 mutation carriers. Maturitas 2010;66:310–14
   PubMed Web of Science ®Google Scholar
• Shifren JL, Nahum R, Mazer NA. Incidence of sexual dysfunction in surgically menopausal women. Menopause 1998;3:189–90
   Google Scholar
• Rocca WA, Grossardt BR, de Andrade M, et al. Survival patterns after oophorectomy in premenopausal women: a population-based cohort study. Lancet Oncol 2006;7:821–8
   PubMed Web of Science ®Google Scholar
• Ossewaarde ME, Bots ML, Verbeek AL, et al. Age at menopause, cause-specific mortality and total life expectancy. Epidemiology 2005;16:556–62
   PubMed Web of Science ®Google Scholar
• Gallagher JC. Effect of early menopause on bone mineral density and fractures. Menopause 2007;14:567–71
   PubMed Web of Science ®Google Scholar
• Fakkert IE, Abma EM, Westrik IG, et al. Bone mineral density and fractures after risk-reducing salpingo-oophorectomy in women at increased risk for breast and ovarian cancer. Eur J Cancer 2015;51:400–8
   PubMed Web of Science ®Google Scholar
• Maclennan AH, Broadbent JL, Lester S, et al. Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes. Cochrane Database Syst Rev 2004;4:CD002978
   PubMedGoogle Scholar
• Shifren JL, Schiff I. Role of hormone therapy in the management of menopause. Obstet Gynecol 2010;115:839–55
   PubMed Web of Science ®Google Scholar
• Vermeulen RFM, Beurden MV, Kieffer JM, et al. Hormone replacement therapy after risk-reducing salpingo-oophorectomy minimises endocrine and sexual problems: a prospective study. Eur J Cancer 2017;84:159–67
   PubMed Web of Science ®Google Scholar
• Holmberg L, Iversen OE, Rudenstam CM, et al. Increased risk of recurrence after hormone replacement therapy in breast cancer survivors. J Natl Cancer Inst 2008;100:475–82
   PubMed Web of Science ®Google Scholar
• Rebbeck TR, Friebel T, Wagner T, et al. Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. JCO 2005;23:7804–10
   PubMed Web of Science ®Google Scholar
• Eisen A, Lubinski J, Gronwald J, et al. Hormone therapy and the risk of breast cancer in BRCA1 mutation carriers. J Natl Cancer Inst 2008;100:1361–7
   PubMed Web of Science ®Google Scholar
• Armstrong K, Schwartz JS, Randall T, et al. Hormone replacement therapy and life expectancy after prophylactic oophorectomy in women with BRCA1/2 mutations: a decision analysis. JCO 2004;22:1045–54
   PubMed Web of Science ®Google Scholar
• Gabriel CA, Tigges-Cardwell J, Stopfer J, et al. Use of total abdominal hysterectomy and hormone replacement therapy in BRCA1 and BRCA2 mutation carriers undergoing risk-reducing salpingo-oophorectomy. Familial Cancer 2009;8:23–28
   PubMed Web of Science ®Google Scholar
• Domchek SMFT, Neuhausen SL, PROSE Consortium, et al. Is hormone replacement therapy (HRT) following risk-reducing salpingo-oophorectomy (RRSO) in BRCA1 (B1)- and BRCA2 (B2)-mutation carriers associated with an increased risk of breast cancer? [abstract]. JCO 2011;29:Abstract 1501
   Web of Science ®Google Scholar
• Kotsopoulos J, Huzarski T, Gronwald J, et al. Hormone replacement therapy after menopause and risk of breast cancer in BRCA1 mutation carriers: a case-control study. Breast Cancer Res Treat 2016;155:365–73
   PubMed Web of Science ®Google Scholar
• Kotsopoulos J, Gronwald J, Karlan BY, et al. Hormone replacement therapy after oophorectomy and breast cancer risk among BRCA1 mutation carriers. JAMA Oncol 2018;4:1059–65
   PubMed Web of Science ®Google Scholar
• Oncoline. Guideline hereditary and familial ovarian cancer in 2015. 2015. www.oncoline.nl
   Google Scholar
• Institut National du Cancer. Chirurgie prophylactique des cancers avec prédisposition génétique Cancer de L'Ovaire. 2009:12–3. www.e-cancer.fr
   Google Scholar
• Ginecologia SPD. Consenso Nacional sobre MENOPAUSA. 2016
   Google Scholar
• Sarri G, Davies M, Lumsden MA. Diagnosis and management of menopause: summary of NICE guidance. BMJ 2015;351:h5746
   PubMed Web of Science ®Google Scholar
• Stanczyk FZ, Hapgood JP, Winer S, et al. Progestogens used in postmenopausal hormone therapy: differences in their pharmacological properties, intracellular actions, and clinical effects. Endocrine Rev 2013;34:171–208
   PubMed Web of Science ®Google Scholar
• Ziaei S, Moghasemi M, Faghihzadeh S. Comparative effects of conventional hormone replacement therapy and tibolone on climacteric symptoms and sexual dysfunction in postmenopausal women. Climacteric 2010;13:147–56
   PubMed Web of Science ®Google Scholar
• Wu MH, Pan HA, Wang ST, et al. Quality of life and sexuality changes in postmenopausal women receiving tibolone therapy. Climacteric 2001;4:314–19
   PubMedGoogle Scholar
• Nijland EA, Nathorst-Boos J, Palacios S, et al. Improved bleeding profile and tolerability of tibolone versus transdermal E2/NETA treatment in postmenopausal women with female sexual dysfunction. Climacteric 2009;12:114–21
   PubMed Web of Science ®Google Scholar
• Lundstrom E, Hirschberg AL, Soderqvist G. Digitized assessment of mammographic breast density–effects of continuous combined hormone therapy, tibolone and black cohosh compared to placebo. Maturitas 2011;70:361–4
   PubMed Web of Science ®Google Scholar
• Valdivia I, Campodonico I, Tapia A, et al. Effects of tibolone and continuous combined hormone therapy on mammographic breast density and breast histochemical markers in postmenopausal women. Fertil Steril 2004;81:617–23
   PubMed Web of Science ®Google Scholar
• Colacurci N, Fornaro F, De Franciscis P, et al. Effects of different types of hormone replacement therapy on mammographic density. Maturitas 2001;40:159–64
   PubMed Web of Science ®Google Scholar
• Chlebowski RT, Hendrix SL, Langer RD, et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA 2003;289:3243–53
   PubMed Web of Science ®Google Scholar
• Beral V. Million Women Study C. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003;362:419–27
   PubMed Web of Science ®Google Scholar
• Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004;291:1701–12
   PubMed Web of Science ®Google Scholar
• Cobin RH, Goodman NF, Committee ARES. American Association of Clinical Endocrinologists and American College of Endocrinology Position Statement on Menopause-2017 Update. Endocr Pract 2017;23:869–80
   PubMed Web of Science ®Google Scholar
• Baber RJ, Panay N, Fenton A, et al. 2016 IMS Recommendations on women's midlife health and menopause hormone therapy. Climacteric 2016;19:109–50
   PubMed Web of Science ®Google Scholar
• Marjoribanks J, Farquhar C, Roberts H, et al. Long-term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database Syst Rev 2017;1:CD004143
   PubMed Web of Science ®Google Scholar
• Shu CA, Pike MC, Jotwani AR, et al. Uterine cancer after risk-reducing salpingo-oophorectomy without hysterectomy in women with BRCA mutations. JAMA Oncol 2016;2:1434–40
   PubMed Web of Science ®Google Scholar
• Beiner ME, Finch A, Rosen B, et al. The risk of endometrial cancer in women with BRCA1 and BRCA2 mutations. A Prospective Study. Gynecol Oncol 2007;104:7–10
   PubMed Web of Science ®Google Scholar
• Levine DA, Lin O, Barakat RR, et al. Risk of endometrial carcinoma associated with BRCA mutation. Gynecol Oncol 2001;80:395–98
   PubMed Web of Science ®Google Scholar
• Aarts JW, Nieboer TE, Johnson N, et al. Surgical approach to hysterectomy for benign gynaecological disease. Cochrane Database Syst Rev 2015;12:CD003677
   Google Scholar
• National Comprehensive Cancer Network. Genetic/Familial High-Risk Assessment: Breast and Ovarian Cancer. https://www.genomeweb.com/sites/default/files/nccn_2017.pdf
   Google Scholar
• Garber JE, Hartman AR. Prophylactic oophorectomy and hormone replacement therapy: protection at what price? JCO 2004;22:978–80
   PubMed Web of Science ®Google Scholar
• Chlebowski RT, Prentice RL. Menopausal hormone therapy in BRCA1 mutation carriers: uncertainty and caution. J Natl Cancer Inst 2008;100:1341–3
   PubMedGoogle Scholar
• Reid R, Abramson BL, Blake J, et al. Managing menopause. J Obstet Gynaecol Canada 2014;36:830–3
   PubMedGoogle Scholar
• Sellers TA, Mink PJ, Cerhan JR, et al. The role of hormone replacement therapy in the risk for breast cancer and total mortality in women with a family history of breast cancer. Ann Intern Med 1997;127:973–80
   PubMed Web of Science ®Google Scholar
• Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer. Lancet 1997;350:1047–59
   PubMed Web of Science ®Google Scholar
• Royal College of Obstetricians and Gynaecologists. Management of women with a Genetic Predisposition to Gynaecological Cancers. (Scientific Impact Paper No. 48). 2015. https://www.rcog.org.uk/en/guidelines-research-services/guidelines/sip48/
   Google Scholar
• Mutch D, Denny L, Quinn M. Hereditary gynecologic cancers. Int J Gynaecol Obstet 2014;124:189–92
   PubMed Web of Science ®Google Scholar
• National Breast And Ovarian Cancer Centre. Recommendations for the management of women at high risk of ovarian cancer. 2011. https://canceraustralia.gov.au/publications-and-resources/clinical-practice-guidelines/recommendations-management-women-high-risk-ovarian-cancer
   Google Scholar
• Madalinska JB, van Beurden M, Bleiker EM, et al. The impact of hormone replacement therapy on menopausal symptoms in younger high-risk women after prophylactic salpingo-oophorectomy. JCO 2006;24:3576–82
   PubMed Web of Science ®Google Scholar
• Den Norske Legeforening. The Norwegian Guidelines of Gynecologic Oncology: Ovarian-, tubal-, and peritoneal cancer. 2016. http://legeforeningen.no
   Google Scholar
• Cancer Society of Finland. National guideline for diagnostics and treatment of breast cancer. https://www.cancersociety.fi/
   Google Scholar
• Danish Breast Cancer Cooperative Group. Danish Breast Cancer Group recommendations. Chapter 19: Arvelig cancer mammae – ovarii. 2016. http://www.dbcg.dk/
   Google Scholar
• Eisen A, Lubinski J, Klijn J, et al. Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study. JCO 2005;23:7491–6
   PubMed Web of Science ®Google Scholar
• Interdisziplinäre S3-Leitlinie für die Diagnostik, Therapie und Nachsorge des Mammakarzinoms. Leitlinienprogramm Onkologie. 2012:46–50. https://www.senologie.org/fileadmin/downloads/S3-Brustkrebs-v2012-OL-Langversion.pdf
   Google Scholar
• Robson M, Hensley M, Barakat R, et al. Quality of life in women at risk for ovarian cancer who have undergone risk-reducing oophorectomy. Gynecol Oncol 2003;89:281–7
   PubMed Web of Science ®Google Scholar